MGC018, an anti-B7-H3 ADC, is being combined with lorigerlimab (a PD-1/CTLA-4 bispecific antibody) in a phase I/Ib trial (NCT05293496) for B7-H3-expressing cancers. The gene discussed is CD276; the disease is cancer.